Alliance Pharma PLC (ISE:APH)

Alliance Pharma PLC (ISE:APH)


Share Price
78.60 p
Change
0.5 (0.64 %)
Market Cap
£407.47 m
Proactive Investors - Run By Investors For Investors

Alliance Pharma PLC RNS Release

Annual Report and Notice of AGM


RNS Number : 3729W
Alliance Pharma PLC
16 April 2019
 

 

 

                                            16 April 2019

 

 

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

 

Annual Report & Accounts and Notice of AGM

 

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that the following documents are now available on the Company's website, www.alliancepharmaceuticals.com:

 

·      The Annual Report & Accounts for the year ended 31 December 2018

 

·      The Notice of the 2019 Annual General Meeting ("AGM"), which will be held at 10.00am on 23 May 2019 at the offices of Buchanan, 107 Cheapside, London EC2V 6DN

 

Printed copies of all the documents have been posted to those shareholders who have opted out of receiving electronic communications from the Company.

 

Printed copies of the documents are also available by contacting Buchanan by email at [email protected] or by telephoning Buchanan on 020 7466 5000.

 

 

 

 

For further information:

 

Alliance Pharma plc

+ 44 (0)1249 466966

Peter Butterfield, Chief Executive Officer

 

Andrew Franklin, Chief Financial Officer

 

www.alliancepharma.co.uk

 

Buchanan

+ 44 (0)20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff

 

 

 

Numis Securities Limited

+ 44 (0)20 7260 1000

Nominated Adviser: Freddie Barnfield

 

Corporate Broking: James Black

 

 

Investec Bank plc

+ 44 (0)20 7597 5970

Corporate Finance: Daniel Adams / Ed Thomas

 

Corporate Broking: Patrick Robb / Tejas Padalkar

 

 

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with affiliate offices in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.

We currently own or license the rights to more than 90 pharmaceutical and consumer healthcare products, which are managed on a portfolio basis according to their growth potential. Promotional investment is focussed on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.

Our tried and tested 'Buy and Build' strategy, allows us to benefit both from organic growth opportunities and from enhancing our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our websitewww.alliancepharmaceuticals.com  

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCIFMMTMBABBLL

Alliance Pharma PLC Timeline

Newswire
January 21 2019
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use